Catalyst Brief

← Calendar

Readoutin 14d

RayzeBio, Inc. — RYZ101

Phase 3 primary completion: Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy.

Date
Dec 2026
Type
Readout
Indication
GEP-NET

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.